Jump to content



Photo

Tachyphylaxis


  • Please log in to reply
No replies to this topic

#1 fishinghat

fishinghat

    Site Partners

  • Active Members
  • PipPipPipPipPipPipPipPipPipPipPipPipPipPipPipPipPipPip
  • 11,998 posts
  • LocationMissouri

Posted 11 January 2020 - 09:48 AM

https://www.ncbi.nlm...pubmed/30439676
J Affect Disord. 2019 Feb 15;245:488-497. doi: 10.1016/j.jad.2018.10.357. Epub 2018 Oct 28.
Tachyphylaxis in major depressive disorder: A review of the current state of research.
Abstract
BACKGROUND:
Patients with major depressive disorder (MDD) often experience a re-emergence or worsening of symptoms despite ongoing treatment with previously effective antidepressant pharmacotherapy. This lost or reduced antidepressant response during maintenance, referred to as tachyphylaxis, negatively impacts treatment outcomes and quality of life for patients with MDD. This review assesses the prevalence of antidepressant tachyphylaxis as well as the evidence for interventions to manage it.
RESULTS:
Rates of tachyphylaxis varied from 9% to 57% depending on the patient population and duration of follow-up. Limited evidence suggests potentially beneficial strategies for managing tachyphylaxis, including change in antidepressant dosing, switch of class of antidepressant medication, augmentation or combination pharmacotherapy, and psychotherapy.

https://www.ncbi.nlm...pubmed/30041180
Psychother Psychosom. 2018;87(5):268-275. doi: 10.1159/000491550. Epub 2018 Jul 24.
Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review.
Abstract
BACKGROUND:
Following remission of an anxiety disorder or a depressive disorder, antidepressants are frequently discontinued and in the case of symptom occurrence reinstated. Reinstatement of antidepressants seems less effective in some patients, but an overview is lacking. This systematic review aimed to provide insight into the magnitude and risk factors of response failure after reinstatement of antidepressants in patients with anxiety disorders, depressive disorders, obsessive-compulsive disorder (OCD), or posttraumatic stress disorder (PTSD).
METHOD:
PubMed, Embase, and trial registers were systematically searched for studies in which patients: (1) had an anxiety disorder, a depressive disorder, OCD, or PTSD and (2) experienced failure to respond after reinstatement of a previously effective antidepressant.
RESULTS:
Ten studies reported failure to respond following antidepressant reinstatement. The phenomenon was observed in 16.5% of patients with a depressive disorder, OCD, and social phobia and occurred in all common classes of antidepressants. The range of response failure was broad, varying between 3.8 and 42.9% across studies. No risk factors for failure to respond were investigated. The overall study quality was limited.
CONCLUSION:
Research investigating response failure is scarce and the study quality limited. Response failure occurred in a substantial minority of patients. Contributors to the relevance of this phenomenon are the prevalence of the investigated disorders, the number of patients being treated with antidepressants, and the occurrence of response failure for all common classes of antidepressants. This systematic review highlights the need for studies systematically investigating this phenomenon and associated risk factors.





0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users